SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 164.32-2.5%Jan 16 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: P.M.Freedman who wrote (1105)8/17/1999 6:52:00 AM
From: Harold Engstrom  Read Replies (2) of 1686
 
PMF,

Again, you have not indicated anything that points to Biogen being in a vulnerable position. Biogen has repeatedly won cases against Berlex, and for good reasons. While respecting your beliefs, I question their foundation: you have cited no facts.

The company manufactures only Avonex for sale. However, the company does not consider itself a one-drug company - it does license and receive royalties on a $2B drug called IntronA and receives royalties on 2 other drugs as well.

Personally, I appreciate your pointing out the stock's potential downside. But, I'm sure you can understand why some would get frustrated with your style: you don't cite facts, you often mention other stocks that you like much more, and you seem to make conclusions from statistics that do not necessarily follow.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News